63. 特発性血小板減少性紫斑病 Idiopathic thrombocytopenic purpura Clinical trials / Disease details
臨床試験数 : 363 / 薬物数 : 212 - (DrugBank : 43) / 標的遺伝子数 : 47 - 標的パスウェイ数 : 138
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05232149 (ClinicalTrials.gov) | February 2022 | 20/12/2021 | A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia | A Randomized, Multi-center, Adaptive Phase IIa/IIb Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Persistent or Chronic Primary Immune Thrombocytopenia | Primary Immune Thrombocytopenia | Drug: Orelabrutinib( lower dose);Drug: Orelabrutinib( higher dose) | Beijing InnoCare Pharma Tech Co., Ltd. | NULL | Not yet recruiting | 18 Years | 80 Years | All | 30 | Phase 2 | China |
| 2 | NCT05020288 (ClinicalTrials.gov) | September 1, 2021 | 12/8/2021 | A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP | A Prospective, Open-label, Multicenter,Single-armed Study of Orelabrutinib in the Treatment of Refractory Primary Immune Thrombocytopenia (ITP) | Immune Thrombocytopenia;Bruton's Tyrosine Kinase | Drug: Orelabrutinib | Shandong University | NULL | Not yet recruiting | 18 Years | 70 Years | All | 40 | Phase 2 | NULL |